Overview

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2021-05-04
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG3667 in multiple daily oral doses in subjects with moderate to severe plaque psoriasis.
Phase:
Phase 1
Details
Lead Sponsor:
Galapagos NV